AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

BIOXYNE LTD

0.021

+0.000

Volume:3.18M

Turnover:70.41K

Market Cap:45.46M

PE:18.82

High:0.023

Open:0.022

Low:0.021

Close:0.021

Loading ...

Overview Company News Filings

BRIEF-Bioxyne Posts A$7.2 Mln Q3 Revenue

Bioxyne Limited's (ASX:BXN) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Simply Wall St.

Bioxyne Signs AU$7 Million Manufacturing, Supply Agreement

MT Newswires Live

BRIEF-Bioxyne Signs Exclusive A$7M Manufacturing And Supply Agreement With NectarTek Australia

Bioxyne Ltd - Signs Exclusive a$7M Manufacturing and Supply Agreement With Nectartek Australia

THOMSON REUTERS

Bioxyne to Raise AU$3 Million Via Placement

MT Newswires Live

BRIEF-Bioxyne To Raise A$3 Mln At A$0.025 Per Share

Bioxyne Ltd - to Raise a$3 Mln at a$0.025 per Share

THOMSON REUTERS

Bioxyne Ltd-Proposed Issue of Securities - Bxn

THOMSON REUTERS

BRIEF-Bioxyne Seeks Trading Halt

Bioxyne Limited (ASX:BXN) Shares Slammed 46% But Getting In Cheap Might Be Difficult Regardless

Simply Wall St.

Bioxyne's (ASX:BXN) Earnings Aren't As Good As They Appear

Simply Wall St.

Shareholders have faith in loss-making Bioxyne (ASX:BXN) as stock climbs 47% in past week, taking one-year gain to 267%

Simply Wall St.

Corrected-Bioxyne Ltd - a$8.1 Mln (Not a$6.1 Mln) Q2 Revenue

THOMSON REUTERS

BRIEF-Bioxyne Posts A$8.1 Mln Q2 Revenue

Bioxyne Ltd - a$6.1 Mln Q2 Revenue

THOMSON REUTERS

Bioxyne Ltd - Expected Result Due to Growing Customer Base, Others

THOMSON REUTERS

Bioxyne Ltd - Upgraded Revenue Forecast for FY2025 Increased to a$25 Mln

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BXN.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BXN.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BXN.AU\",,,,,undefined,":{"symbol":"BXN.AU","market":"AU","secType":"STK","nameCN":"BIOXYNE LTD","latestPrice":0.021,"timestamp":1746079920000,"preClose":0.021,"halted":0,"volume":3184878,"delay":0,"nameEN":"BIOXYNE LTD","floatShares":513253399,"shares":2164828732,"eps":0.001116,"marketStatus":"Not Yet Opened","change":0,"latestTime":"05-01 16:12:00 AEST","open":0.022,"high":0.023,"low":0.021,"amount":70411,"amplitude":0.095238,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.001116,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1746144000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.021,"openAndCloseTimeList":[[1746057600000,1746079200000]],"volumeRatio":0.7336181738858483,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BXN.AU\",,,,,undefined,":{"symbol":"BXN.AU","floatShares":513253399,"roa":"18.73%","roe":"51.99%","lyrEps":-0.006903,"volumeRatio":0.7336181738858483,"shares":2164828732,"dividePrice":0,"high":0.023,"amplitude":0.095238,"preClose":0.021,"low":0.021,"week52Low":0.004,"pbRate":"6.32","psRate":"2.62","week52High":0.053,"institutionHeld":0,"latestPrice":0.021,"eps":0.001116,"divideRate":0,"volume":3184878,"delay":0,"ttmEps":0.001116,"open":0.022,"prevYearClose":0.027,"prevWeekClose":0.024,"prevMonthClose":0.021,"prevQuarterClose":0.028,"fiveDayClose":0.024,"twentyDayClose":0.028,"sixtyDayClose":0.046},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BXN.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530499793","title":"BRIEF-Bioxyne Posts A$7.2 Mln Q3 Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2530499793","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530499793?lang=en_us&edition=fundamental","pubTime":"2025-04-28 09:53","pubTimestamp":1745805222,"startTime":"0","endTime":"0","summary":"BRIEF-Bioxyne Posts A$7.2 Mln Q3 RevenueApril 28 (Reuters) - Bioxyne Ltd BXN.AX:A$7.2 MILLION Q3 REVENUE]Further company coverage: BXN.AX ((Reuters.Briefs@thomsonreuters.com;;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nFWN3R4098:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BXN.AU"],"gpt_icon":0},{"id":"2528201160","title":"Bioxyne Limited's (ASX:BXN) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?","url":"https://stock-news.laohu8.com/highlight/detail?id=2528201160","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528201160?lang=en_us&edition=fundamental","pubTime":"2025-04-19 04:02","pubTimestamp":1745006575,"startTime":"0","endTime":"0","summary":"It is hard to get excited after looking at Bioxyne's  recent performance, when its stock has declined 14% over the past month. However, stock prices are usually driven by a company’s financials over the long term, which in this case look pretty respectable. Particularly, we will be paying attention to Bioxyne's  ROE today.Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. In simpler terms, it measures the profitability of a company in relation to shareholder's equity.  Our free stock report includes 3 warning signs investors should be aware of before investing in Bioxyne.Return on Equity = Net Profit  ÷ Shareholders' Equity. So, based on the above formula, the ROE for Bioxyne is:","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioxyne-limiteds-asx-bxn-stock-200255960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7508","BXN.AU","BK7111"],"gpt_icon":0},{"id":"2524031104","title":"Bioxyne Signs AU$7 Million Manufacturing, Supply Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2524031104","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524031104?lang=en_us&edition=fundamental","pubTime":"2025-04-03 12:49","pubTimestamp":1743655743,"startTime":"0","endTime":"0","summary":"Bioxyne  signed an exclusive AU$7 million manufacturing and supply agreement with its existing customer, NectarTek Australia, according to a Thursday Australian bourse filing.Its unit Breathe Life Sciences was named as the exclusive manufacturer of all NectarTek products for distribution in Australia, the UK, and Germany.The agreement includes volume commitments which are expected to generate at least AU$7 million in revenue for Bioxyne in the fiscal year 2026.The contract includes minimum order volumes of AU$3.6 million of pastilles, AU$2.5 million of packed flower products, AU$500,000 of vapes, and AU$500,000 of oral mucosal oils and other products.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","XJO.AU","XKO.AU","XAO.AU","BXN.AU","BK7111"],"gpt_icon":0},{"id":"2524642286","title":"BRIEF-Bioxyne Signs Exclusive A$7M Manufacturing And Supply Agreement With NectarTek Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2524642286","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524642286?lang=en_us&edition=fundamental","pubTime":"2025-04-03 09:05","pubTimestamp":1743642320,"startTime":"0","endTime":"0","summary":"BRIEF-Bioxyne Signs Exclusive A$7M Manufacturing And Supply Agreement With NectarTek AustraliaApril 3 (Reuters) - Bioxyne Ltd BXN.AX:SIGNS EXCLUSIVE A$7M MANUFACTURING AND SUPPLY AGREEMENT WITH NECTAR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nFWN3QG1BW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7111","BXN.AU"],"gpt_icon":0},{"id":"2524441004","title":"Bioxyne Ltd -  Signs Exclusive a$7M Manufacturing and Supply Agreement With Nectartek Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2524441004","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524441004?lang=en_us&edition=fundamental","pubTime":"2025-04-03 05:33","pubTimestamp":1743629595,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QG1BW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7111","BXN.AU","BK7508"],"gpt_icon":0},{"id":"2521446515","title":"Bioxyne to Raise AU$3 Million Via Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2521446515","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521446515?lang=en_us&edition=fundamental","pubTime":"2025-03-21 11:12","pubTimestamp":1742526769,"startTime":"0","endTime":"0","summary":"Bioxyne  received commitments to raise AU$3 million via the placing of 120 million new shares at AU$0.025 apiece, according to a Friday Australian bourse filing.It will also issue 60 million options on the basis of one option for every two new shares, with an exercise price of AU$0.05 and an expiry date of two years from the date of issue.It will use the proceeds to support its expansion into European markets as well as the establishment and certification of medical cannabis manufacturing facilities in the UK and Czechia.Its directors will participate in the amount of AU$110,000, subject to shareholder approval.Alpine Capital was the sole lead manager and book runner to the placement.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7111","BXN.AU"],"gpt_icon":0},{"id":"2521414202","title":"BRIEF-Bioxyne To Raise A$3 Mln At A$0.025 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2521414202","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521414202?lang=en_us&edition=fundamental","pubTime":"2025-03-21 09:20","pubTimestamp":1742520038,"startTime":"0","endTime":"0","summary":"BRIEF-Bioxyne To Raise A$3 Mln At A$0.025 Per ShareMarch 21 (Reuters) - Bioxyne Ltd BXN.AX:TO RAISE A$3 MILLION AT A$0.025 PER SHAREFurther company coverage: BXN.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nFWN3Q318P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BXN.AU","BK7111","BK7508"],"gpt_icon":0},{"id":"2521132894","title":"Bioxyne Ltd - to Raise a$3 Mln at a$0.025 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2521132894","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521132894?lang=en_us&edition=fundamental","pubTime":"2025-03-21 07:30","pubTimestamp":1742513452,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nFWN3Q318P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BXN.AU","BK7111","BK7508"],"gpt_icon":0},{"id":"2521284413","title":"Bioxyne Ltd-Proposed Issue of Securities - Bxn","url":"https://stock-news.laohu8.com/highlight/detail?id=2521284413","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521284413?lang=en_us&edition=fundamental","pubTime":"2025-03-21 07:30","pubTimestamp":1742513431,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nTUE1KWYYQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7111","BXN.AU","BK7508"],"gpt_icon":0},{"id":"2520548769","title":"BRIEF-Bioxyne Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2520548769","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520548769?lang=en_us&edition=fundamental","pubTime":"2025-03-19 07:06","pubTimestamp":1742339187,"startTime":"0","endTime":"0","summary":"BRIEF-Bioxyne Seeks Trading HaltMarch 19 (Reuters) - Bioxyne BXN.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT ON CAPITAL RAISINGFurther company coverage: BXN.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nFWN3Q114V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7111","BXN.AU"],"gpt_icon":0},{"id":"2518036144","title":"Bioxyne Limited (ASX:BXN) Shares Slammed 46% But Getting In Cheap Might Be Difficult Regardless","url":"https://stock-news.laohu8.com/highlight/detail?id=2518036144","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518036144?lang=en_us&edition=fundamental","pubTime":"2025-03-12 04:54","pubTimestamp":1741726444,"startTime":"0","endTime":"0","summary":"The Bioxyne Limited ( ASX:BXN ) share price has softened a substantial 46% over the previous 30 days, handing back much...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/5221000-choice2-main-header/1585186851278","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/5221000-choice2-main-header/1585186851278"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/household/asx-bxn/bioxyne-shares/news/bioxyne-limited-asxbxn-shares-slammed-46-but-getting-in-chea","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","BXN.AU","BK7111"],"gpt_icon":0},{"id":"2518420893","title":"Bioxyne's (ASX:BXN) Earnings Aren't As Good As They Appear","url":"https://stock-news.laohu8.com/highlight/detail?id=2518420893","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518420893?lang=en_us&edition=fundamental","pubTime":"2025-03-09 07:03","pubTimestamp":1741475020,"startTime":"0","endTime":"0","summary":"Bioxyne Limited's  stock rose after it released a robust earnings report. Despite the strong profit numbers, we believe that there are some deeper issues which investors should look into.Many investors haven't heard of the accrual ratio from cashflow, but it is actually a useful measure of how well a company's profit is backed up by free cash flow  during a given period. The accrual ratio subtracts the FCF from the profit for a given period, and divides the result by the average operating assets of the company over that time. You could think of the accrual ratio from cashflow as the 'non-FCF profit ratio'.Bioxyne was losing money three years ago. And even focusing only on the last twelve months, we don't have a meaningful growth rate because it made a loss a yea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioxynes-asx-bxn-earnings-arent-230340554.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BXN.AU"],"gpt_icon":0},{"id":"2508925319","title":"Shareholders have faith in loss-making Bioxyne (ASX:BXN) as stock climbs 47% in past week, taking one-year gain to 267%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508925319","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508925319?lang=en_us&edition=fundamental","pubTime":"2025-02-01 04:17","pubTimestamp":1738354622,"startTime":"0","endTime":"0","summary":"Unfortunately, investing is risky - companies can and do go bankrupt. But when you pick a company that is really flourishing, you can make more than 100%. For example, the Bioxyne Limited  share price has soared 267% in the last 1 year. Most would be very happy with that, especially in just one year!Shareholders are also celebrating an even better 267% rise, over the last three months. And shareholders have also done well over the long term, with an increase of 110% in the last three years.The past week has proven to be lucrative for Bioxyne investors, so let's see if fundamentals drove the company's one-year performance.Bioxyne grew its revenue by 82% last year. That's well above most other pre-profit companies. Meanwhile, the market has paid attention, sending the share price soaring 267% in response. That sort of revenue growth is bound to attract attention, even if the company doesn't turn a profit. Given the positive sentiment around the stock we're cautious, but there's no doubt ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shareholders-faith-loss-making-bioxyne-201702389.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BXN.AU","BK7111","BK7508"],"gpt_icon":0},{"id":"2506536229","title":"Corrected-Bioxyne Ltd - a$8.1 Mln (Not a$6.1 Mln) Q2 Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2506536229","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506536229?lang=en_us&edition=fundamental","pubTime":"2025-01-28 07:02","pubTimestamp":1738018950,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250127:nL5N3ON21D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7111","BXN.AU","BK7508"],"gpt_icon":0},{"id":"2506536015","title":"BRIEF-Bioxyne Posts A$8.1 Mln Q2 Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2506536015","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506536015?lang=en_us&edition=fundamental","pubTime":"2025-01-28 07:02","pubTimestamp":1738018950,"startTime":"0","endTime":"0","summary":"BRIEF-Bioxyne Posts A$8.1 Mln Q2 RevenueJan 28 (Reuters) - Bioxyne Ltd BXN.AX:A$8.1 MILLION (NOT A$6.1 MILLION) Q2 REVENUEFurther company coverage: BXN.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250127:nL5N3ON21D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BXN.AU"],"gpt_icon":0},{"id":"2506653371","title":"Bioxyne Ltd - a$6.1 Mln Q2 Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2506653371","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506653371?lang=en_us&edition=fundamental","pubTime":"2025-01-28 06:20","pubTimestamp":1738016457,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250127:nFWN3ON16P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BXN.AU","BK7508","BK7111"],"gpt_icon":0},{"id":"2505031697","title":"Bioxyne Ltd - Expected Result Due to  Growing Customer Base, Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2505031697","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505031697?lang=en_us&edition=fundamental","pubTime":"2025-01-23 11:42","pubTimestamp":1737603756,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250123:nFWN3OI0OZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7111","BK7508","BXN.AU"],"gpt_icon":0},{"id":"2505031613","title":"Bioxyne Ltd -  Upgraded Revenue Forecast for FY2025 Increased to a$25 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2505031613","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505031613?lang=en_us&edition=fundamental","pubTime":"2025-01-23 11:42","pubTimestamp":1737603756,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250123:nFWN3OI0OZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BXN.AU","BK7508","BK7111"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BXN.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BXN.AU\",market:\"AU\",,,undefined,":[]}}